Göttingen, Germany, 9 October 2009. DeveloGen AG, a biotechnology
company focused on the discovery and development of novel therapies
for diabetes and other metabolic and endocrine disorders announced
today that a team of scientist who published an article in the
Journal of Medicinal Chemistry in the field of beta cell regeneration
was awarded the renowned Phoenix Science Award 2009 in the category
pharmaceutical chemistry. The award is endowed with 10.000 Euro.

The team of scientists from DeveloGen AG in cooperation with Prof.
Conrad Kunick's laboratory at the Technical University Braunschweig,
Germany, published results which demonstrate that small synthetic
molecules can promote the regeneration of insulin producing beta
cells. In cell culture experiments the team of scientists
demonstrated that highly potent and specific glycogen synthase 3 beta
inhibitors are able to protect beta cells from apoptosis and
stimulate their proliferation.

Cord Dohrmann, CEO of DeveloGen AG, said: "Receiving the Phoenix
Science Award is further confirmation of the worldwide leading work
conducted at DeveloGen in the field of beta cell regeneration.
Together with Prof. Kunick we were able to generate important
insights about how beta cells can be protected from apoptosis and
stimulated to proliferate. This is an important step towards the
discovery and development of innovative and potentially disease
modifying therapies for the treatment of diabetes."

The title of the publication is: "9-Cyano-1-azapaullone
(Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) Inhibitor
Activating Pancreatic Beta Cell Protection and Replication". The
article was published in April 2008 in the Journal of Medicinal
Chemistry.

About Diabetes
Diabetes is a global epidemic with devastating human, social and
economic consequences. In 2007 it was estimated that 246 million
people worldwide have diabetes, representing roughly 6% of the adult
population. The number is expected to reach 380 million by 2025,
representing over 7% of the adult population. Diabetes/obesity is the
fastest growing disease in the USA, afflicting one in four Americans
and accounting for well over 30% of the Medicare budget.

About DeveloGen AG
DeveloGen AG is a biopharmaceutical company engaged in the discovery
and development of novel therapeutics for the treatment of metabolic
and endocrine diseases. The Company has a highly innovative and deep
preclinical discovery pipeline addressing the key drivers in the
development of diabetes and obesity such as insulin resistance and
loss of insulin-producing beta cells. This pipeline includes programs
for the potential treatment of obesity through orally available small
molecules based on novel and proprietary targets as well as growth
factors targeting beta-cell regeneration (type 1 and type 2
diabetes). In addition, the Company is developing DG3173
(Somatoprim), a potentially best-in-class somatostatin analogue for
the treatment of acromegaly, carcinoid tumors and diabetic
retinopathy, which has recently successfully completed a Phase 1
clinical trial. DeveloGen is based in Göttingen, Germany. For more
information on DeveloGen, please visit www.develogen.com.

About Phoenix Science Award ("Phoenix Wissenschaftspreis")
Each year, Phoenix Pharma AG awards a price for scientific work in
the areas pharmacology, pharmaceutical biology, pharmaceutical
chemistry and pharmaceutical technology, which has been published in
a German or English journal.

- ends -

Contact

DeveloGen AG
Carsten Dehning
Chief Financial Officer
Marie-Curie-Straße 7
37079 Göttingen, Germany
Phone: +49 551 50558 514
Fax: +49 551 50558 586
dehning@develogen.com


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.